Out-licensing

Method of Treating Brain Tissue Damages by Administering Secretoneurin

Introduction/Background

Brain tissue damage, resulting either from injuries or disorders (eg, neurodegenerative and cerebrovascular diseases), is a leading cause of long-term disability. Due to their pluripotency, embryonic stem cells (ES cells) hold a great promise for treating brain tissue damage. However, ethical and logistical considerations have hampered their use. Use of non-ES pluripotent cells has also been exploited. They include adult bone marrow mesenchymal stem cells or stromal cells and umbilical cord blood cells. Nonetheless, requirements for in vitro expansion and HLA-matching have limited clinical applications of these cells.

Aims/Hypothesis

Thus, there is a need for an alternative method of treating brain tissue damage.

Research

This invention relates to the treatment of brain tissue damage, including administering to a subject in need thereof an effective amount of secretoneurin (SN). Disclosed are methods of promoting angiogenesis or neurogenesis in the brain of subject. Also disclosed are a method of homing of stem cells to the brain of a subject and a method of protecting a neuronal cell from cell death.

Secretoneurin (SN) not only resulted in neuroprotection after neurotoxic insult but also induced increases in stem cell targeting to the ischemic brain, reducing the volume of cerebral infarction and improving neural plasticity.

Conclusion

We have developed a method of treating brain tissue damage, including administering to a subject in need thereof an effective amount of secretoneurin.

Relevance/Opportunity

Please enquire quoting reference no. 13A-940104 regarding licensing or codevelopment partnerships.

Preclinical

US7427597 TWI305496